Myeloma’s new problem: too many good options
For a long time, the post-lenalidomide, post-proteasome inhibitor, post-CD38 setting in multiple myeloma felt like a place where treatment decisions narrowed faster than anyone really wanted to admit.
There is no one product in myeloma standing on the hill alone like an old Samurai’s castle
This is finally beginning to change.
The latest ASCO and EHA datasets point to a more crowded and increasingly complicated landscape. More options and greater competition is a good thing for people dealing with this disease.
Five years ago it was hard to imagine what came next after anti-CD38/LEN-exposed myeloma. Instead it now has multiple phase 2/3 options in development, which means the battle is no longer who has the best activity.
These days it’s about sequencing, immune fitness, tolerability, and whether impressive early disease control can mature into durable clinical benefit.
In this review, we discuss five key regimens to watch out for in myeloma, including an under the radar sleeper option most observers have ignored or missed…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
